Cayman 7α-hydroxy-3-oxo-5β-Cholan-24-oic Acid

Methylprednisolone is a synthetic glucocorticoid, an agonist of glucocorticoid and mineralocorticoid receptors, and an active metabolite of the prodrug 6α-methylprednisolone 21-hemisuccinate (MPS; Item Nos. | ). It transactivates glucocorticoid and mineralocorticoid receptors in a reporter assay using CV-1 cells (EC₅₀s = 2.92 and 2.31 nM for the human receptors, respectively). Methylprednisolone (40 mg/kg) reduces endotoxin-induced complement activation in rabbits. It induces T cell apoptosis and reduces the number of T cell spinal cord infiltrates in a rat model of experimental autoimmune encephalomyelitis (EAE) when administered at a dose of 50 mg/kg. It decreases the number of reactive spinal astrocytes, improves proprioceptive limb placing and coordination, and reduces spinal edema and the number of spinal necrotic cells in a rat model of spinal crush injury. Formulations containing methylprednisolone have been used in the treatment of immune and autoimmune disorders, such as rheumatoid arthritis, systemic lupus erythematosus, psoriasis, corneal ulcers, ulcerative colitis, and allergies, among others.

WARNING This product is not for human or veterinary use.